Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry. - Wikidata - awgldk - TriplyDB

Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry.

Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry.

http://www.wikidata.org/entity/Q43778384

about

Use of biologics and chemotherapy in patients with inflammatory bowel diseases and cancer Elderly patients and inflammatory bowel disease Lymphoproliferative disorders in inflammatory bowel disease patients on immunosuppression: Lessons from other inflammatory disorders How should immunomodulators be optimized when used as combination therapy with anti-tumor necrosis factor agents in the management of inflammatory bowel disease?Optimizing the use of biological therapy in patients with inflammatory bowel disease Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy.Review article: why, when and how to de-escalate therapy in inflammatory bowel diseases.Cancer and immunomodulators in inflammatory bowel diseases.Anal Canal Adenocarcinoma in a Patient with Longstanding Crohn's Disease Arising From Rectal Mucosa that Migrated From a Previously Treated Rectovaginal Fistula Long-term safety of immunomodulators in pediatric inflammatory diseases.The role and advances of immunomodulator therapy for inflammatory bowel disease.Does a personal or family history of malignancy preclude the use of immunomodulators and biologics in IBD.Medical and surgical complications of inflammatory bowel disease in the elderly: a systematic review.Benefits and risks of combining anti-tumor necrosis factor with immunomodulator therapy in pediatric inflammatory bowel disease.Safety of infliximab for the treatment of inflammatory bowel disease: current understanding of the potential for serious adverse events.Inflammatory bowel disease and the elderly: a review.Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study.Thyroid cancer and T lymphoblastic leukemia in Crohn disease: a case report and literature review.Use of Imaging Techniques in Inflammatory Bowel Diseases That Minimize Radiation Exposure.Oral Cancer and Oral Precancerous Lesions in Inflammatory Bowel Diseases: A Systematic Review.Optimizing Biologic Agents in Ulcerative Colitis and Crohn's Disease.Monitoring for Extra-Intestinal Cancers in IBD.Concomitant Therapy with Immunomodulator Enhances Infliximab Durability in Pediatric Inflammatory Bowel Disease.Balancing the risks and benefits of biologic therapy in inflammatory bowel diseases.Anti-TNF-α therapies for the treatment of Crohn's disease: the past, present and future.A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease.Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities.Practical Approaches to "Top-Down" Therapies for Crohn's Disease.Management of Inflammatory Bowel Disease in the Elderly.Understanding the Cautions and Contraindications of Immunomodulator and Biologic Therapies for Use in Inflammatory Bowel Disease.A retrospective comparison of infliximab versus adalimumab as induction and maintenance therapy for Crohn disease.Adalimumab therapy in a patient with Crohn's disease with a giant pelvic paraganglioma after chemotherapy.Challenges in the Diagnosis and Management of Inflammatory Bowel Disease in the Elderly.Risk of Malignancy in a Nationwide Cohort of Elderly Inflammatory Bowel Disease Patients.SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN'S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB.Biologics in pediatric Crohn's disease: is it time to move to an earlier therapeutic approach?Large Registry Epidemiology in IBD.Evidence-based clinical practice guidelines for inflammatory bowel disease.Incidence, management, and course of cancer in patients with inflammatory bowel disease.Unsuspected Small-Bowel Crohn's Disease in Elderly Patients Diagnosed by Video Capsule Endoscopy.

P2860

Q26750190-39071D3B-8968-4516-909F-E2F4C921A04E Q26768270-1C8167DD-0757-48BC-9E42-BC99F2F7BFB8 Q26776151-98D08CB4-BB8A-4953-A5E4-5933AED6D10D Q26777409-F3FE231E-E476-4BA5-A1BA-7938BD21A0EC Q27025513-89A3B581-D9C7-41BA-B03D-6E461587BB6D Q31151474-5FAF02F5-263A-42F6-9F13-37DFFD4391F7 Q35193565-6F2F0B83-D9BB-4C4B-A702-242CCD667547 Q35534959-A050E6DA-E984-4F02-81BD-1FA7F8D7F2C3 Q37073840-2776355C-DDEE-4088-B04C-272672799221 Q38232338-2FCAEF24-E4DC-4FC6-A752-BECD5BE6765D Q38237701-9176B6C9-C887-415C-B3BA-0D6BE7A17E73 Q38253832-8E82A63B-0209-403D-B494-7286BBB8D763 Q38287106-280D7B74-AE08-4FE6-8ED7-C2FABB47BCE0 Q38365848-05D1C4D5-997C-41FC-BEE5-1AB62DFCC544 Q38394816-DCFA417D-502C-4165-B1C0-0EDE033EC537 Q38419578-E205C3DB-D9ED-485F-8BF5-1B5AEA2BE591 Q38425063-628274F3-4281-4B82-A2A3-B1F05C611742 Q38445656-27C71593-431C-4A6C-A4F8-4EBED09CFA24 Q38539966-23ABFE15-CE06-4FF6-A8DC-BA07CC97A8AA Q38545129-057FCCA8-136D-4D7D-85A0-C80C6D1E083E Q38549995-A466E368-9BC9-42E1-BAF5-5729C39C6143 Q38585910-3AA5B8A1-B683-4C69-887C-FDC795B36664 Q38610162-B21EC2DB-1D45-4FB7-9B3F-6EE2C23562F8 Q38630959-BCACE510-A805-4D25-87B8-96249797E9C9 Q38652276-77361B3F-2EC1-4CF7-B6F2-929B2AAA1B64 Q38707864-E4650516-E84C-4902-BD0C-266D19772386 Q38735146-7FEC04D6-672C-4A3F-AE41-E8EE8A6E0300 Q38835478-97718223-C642-49A1-B637-C99A0FD37EE2 Q38844393-0393E844-4C8F-43FB-8837-9CF7531F80FC Q39435409-11F55C70-5D40-4F38-BF21-329FB3A15382 Q40006169-BB25329A-8833-43F9-9550-95898F284EAD Q40066358-8FDDDE16-BDB8-4666-AA47-9196B6ADB092 Q41169995-0B3B6593-A451-4FE5-85E8-210BF280B08F Q47095222-3F7BA804-97AA-442E-BD68-76E9F56D1406 Q47736120-EBCF9B99-6A38-4ED5-85B9-299BB995BE2C Q48736733-38B2C7EA-5BE9-40ED-A35E-8B4A20BC19AC Q49387093-345D87C7-6A55-4166-A3FE-C06E8C2A8F25 Q50079201-0F3CB786-EACF-45A2-B551-C908B3FA724C Q50451653-FEECDD90-0210-4510-B6CE-D2AA33DC2E3C Q55415622-145107CC-F99E-42DF-A966-6873F9414433

P2860

Drug therapies and the risk of malignancy in Crohn's disease: results from the TREAT™ Registry.

http://www.wikidata.org/entity/Q43778384

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh-hant

name

Drug therapies and the risk of ...... ults from the TREAT™ Registry.

@en

Drug therapies and the risk of ...... ults from the TREAT™ Registry.

@nl

type

label

Drug therapies and the risk of ...... ults from the TREAT™ Registry.

@en

Drug therapies and the risk of ...... ults from the TREAT™ Registry.

@nl

prefLabel

Drug therapies and the risk of ...... ults from the TREAT™ Registry.

@en

Drug therapies and the risk of ...... ults from the TREAT™ Registry.

@nl

P1433

Q43778384-B0F4380E-C15F-46C4-AF27-7872DA38A57C

P1476

Q43778384-1BE63522-7A04-458B-8A89-E923D95546A7

P2093

Q43778384-1B945368-4C97-4EB5-ACBF-6541C850D7C4

Q43778384-38434CCA-5E03-4A2C-8D5D-D09E1F28E473

Q43778384-81F1C277-240B-40BB-B42B-3A965F6A2905

Q43778384-DBD12E91-9666-4F3F-A4F6-056F0D698DFF

Q43778384-E45355D8-6E05-40F6-99E1-A68891B63EE7

Q43778384-EC9AF181-5AD8-4BC2-81FF-977E76E14360

P2860

Q43778384-0072C1C3-1A7B-47C0-B5EE-07121FD83960

Q43778384-1055E2D1-BEED-403E-9AAF-7C0780161C55

Q43778384-136F3D7C-B9C0-47C0-83AB-BC1B492B136B

Q43778384-1EC248A7-79AA-451B-AEBE-752B7B397852

Q43778384-20FDC5E0-9226-4C82-BFDF-19E358759E98

Q43778384-27FFE796-E2FA-4F88-BB51-58698F25AC7B

Q43778384-397D3873-B47D-4675-B532-9A46D4B8F8CD

Q43778384-39F51A8E-4596-4B86-AFBD-03E6A9AA6033

Q43778384-43BD822C-D338-4F27-8AE6-6F9C15453A2B

Q43778384-5508C7CB-4461-4529-8EA6-9FAAF9063788

P304

Q43778384-7BD268A0-805B-46BC-93C2-DD55BC67F2F6

P31

Q43778384-1E289046-4BF7-43F4-AF1C-8595E01BC949

P356

Q43778384-DB2780AF-3EDB-4CA5-BFED-55963C0464B7

P407

Q43778384-AEDF80C3-FCE9-45E4-A3BF-55AEDDDC5037

P433

Q43778384-1F983995-9D49-4770-98B7-F795E2C4AB90

P478

Q43778384-15781F11-4CEE-4080-80F4-E3DBC115AB4F

P50

Q43778384-697FC71D-3833-48AD-A12C-78367177AE42

Q43778384-97131A05-C313-4A5A-88FF-FC73FD7D4232

P577

Q43778384-2B6DF1F1-93D7-42F1-8BD8-12CF0F8C7786

P698

Q43778384-91EC28F5-37E4-42A9-8C09-9ACD042CFA10

P356

P1433

The American Journal of Gastroenterology

P1476

Drug therapies and the risk of ...... ults from the TREAT™ Registry.

@en

P2093

Anil Londhe

http://www.w3.org/2001/XMLSchema#string

Bruce A Salzberg

http://www.w3.org/2001/XMLSchema#string

Gary R Lichtenstein

http://www.w3.org/2001/XMLSchema#string

Robert H Diamond

http://www.w3.org/2001/XMLSchema#string

Russell D Cohen

http://www.w3.org/2001/XMLSchema#string

Wayne Langholff

http://www.w3.org/2001/XMLSchema#string

P2860

Management of Crohn's disease in adults

Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine

Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials.

Increased risk for non-melanoma skin cancer in patients with inflammatory bowel disease

Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.

Nonmelanoma skin cancer in inflammatory bowel disease: a review

Azathioprine and anti-TNF alpha therapies in Crohn's disease: a review of pharmacology, clinical efficacy and safety.

Crohn's colitis: the incidence of dysplasia and adenocarcinoma in surgical patients.

Lymphoma risk in inflammatory bowel disease: is it the disease or its treatment?

Risk of nonmelanoma skin cancer with azathioprine use.

P304

212-223

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/AJG.2013.441

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

109

http://www.w3.org/2001/XMLSchema#string

P50

William Jeffery Sandborn

Brian G. Feagan

P577

2014-01-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24394749

http://www.w3.org/2001/XMLSchema#string